• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Pre-Market Session

    5/5/23 9:06:43 AM ET
    $ADTX
    $AKLI
    $BIOL
    $CANF
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ADTX alert in real time by email

    Gainers

    • Nanobiotix (NASDAQ:NBTX) stock increased by 125.6% to $4.58 during Friday's pre-market session. The company's market cap stands at $161.3 million.
    • Star Equity Hldgs (NASDAQ:STRR) stock moved upwards by 24.63% to $0.86. The company's market cap stands at $13.0 million.
    • Aditxt (NASDAQ:ADTX) stock rose 19.94% to $0.79. The market value of their outstanding shares is at $4.0 million.
    • Telesis Bio (NASDAQ:TBIO) shares moved upwards by 17.81% to $3.24. The company's market cap stands at $96.0 million.
    • Fulgent Genetics (NASDAQ:FLGT) stock increased by 15.7% to $33.0. The company's market cap stands at $979.8 million. The company's, Q1 earnings came out today.
    • Owens & Minor (NYSE:OMI) stock moved upwards by 14.98% to $15.58. The company's market cap stands at $1.1 billion. As per the press release, Q1 earnings came out today.

    Losers

    • Soligenix (NASDAQ:SNGX) stock fell 34.6% to $1.49 during Friday's pre-market session. The company's market cap stands at $4.3 million.
    • Biolase (NASDAQ:BIOL) stock decreased by 14.6% to $0.23. The market value of their outstanding shares is at $6.0 million.
    • Celyad Oncology (NASDAQ:CYAD) shares fell 11.74% to $0.6. The market value of their outstanding shares is at $13.5 million.
    • Akili (NASDAQ:AKLI) stock declined by 10.07% to $1.34. The market value of their outstanding shares is at $104.6 million.
    • SI-BONE (NASDAQ:SIBN) stock declined by 9.04% to $22.25. The market value of their outstanding shares is at $782.8 million. As per the press release, Q1 earnings came out 4 days ago.
    • Can Fite Biofarma (AMEX:CANF) shares declined by 8.5% to $1.94. The market value of their outstanding shares is at $7.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADTX
    $AKLI
    $BIOL
    $CANF

    CompanyDatePrice TargetRatingAnalyst
    Nanobiotix S.A.
    $NBTX
    2/6/2026Buy
    TD Cowen
    SI-BONE Inc.
    $SIBN
    1/27/2026$21.00Buy
    TD Cowen
    Owens & Minor Inc.
    $OMI
    11/3/2025$4.00Buy → Neutral
    UBS
    Fulgent Genetics Inc.
    $FLGT
    8/5/2025$30.00Neutral → Buy
    UBS
    Nanobiotix S.A.
    $NBTX
    8/28/2024$12.00Buy
    Guggenheim
    SI-BONE Inc.
    $SIBN
    8/6/2024$27.00 → $19.00Buy
    Needham
    Owens & Minor Inc.
    $OMI
    7/19/2024$24.00 → $19.00Neutral → Buy
    Citigroup
    SI-BONE Inc.
    $SIBN
    3/28/2024$25.00Overweight
    Piper Sandler
    More analyst ratings

    $ADTX
    $AKLI
    $BIOL
    $CANF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Eberwein Jeffrey E. sold $39,794 worth of Series A Preferred Stock (4,365 units at $9.12) and bought $81,503 worth of shares (7,268 units at $11.21), increasing direct ownership by 27% to 1,007,824 units (SEC Form 4)

    4 - Star Equity Holdings, Inc. (0001210708) (Issuer)

    12/31/25 5:02:24 PM ET
    $STRR
    Professional Services
    Consumer Discretionary

    Chief Executive Officer Eberwein Jeffrey E. sold $173,974 worth of Series A Preferred Stock (18,635 units at $9.34) and bought $109,212 worth of shares (9,709 units at $11.25), increasing direct ownership by 23% to 1,000,556 units (SEC Form 4)

    4 - Star Equity Holdings, Inc. (0001210708) (Issuer)

    12/29/25 7:09:34 PM ET
    $STRR
    Professional Services
    Consumer Discretionary

    Chief Executive Officer Eberwein Jeffrey E. bought $2,999,991 worth of shares (287,631 units at $10.43) and sold $2,999,994 worth of Series A Preferred Stock (320,855 units at $9.35), increasing direct ownership by 15% to 810,217 units (SEC Form 4)

    4 - Star Equity Holdings, Inc. (0001210708) (Issuer)

    12/10/25 4:01:17 PM ET
    $STRR
    Professional Services
    Consumer Discretionary

    $ADTX
    $AKLI
    $BIOL
    $CANF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on Nanobiotix

    TD Cowen initiated coverage of Nanobiotix with a rating of Buy

    2/6/26 8:11:18 AM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on SI-BONE with a new price target

    TD Cowen initiated coverage of SI-BONE with a rating of Buy and set a new price target of $21.00

    1/27/26 8:49:24 AM ET
    $SIBN
    Medical/Dental Instruments
    Health Care

    Owens & Minor downgraded by UBS with a new price target

    UBS downgraded Owens & Minor from Buy to Neutral and set a new price target of $4.00

    11/3/25 9:08:29 AM ET
    $OMI
    Medical Specialities
    Health Care

    $ADTX
    $AKLI
    $BIOL
    $CANF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Soligenix to Present at BIO Investment & Growth Summit

    PRINCETON, N.J., Feb. 24, 2026 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Christopher J. Schaber, Ph.D., President & Chief Executive Officer will deliver a corporate presentation at the BIO Investment & Growth Summit at 3:00 PM on Monday, March 2. The BIO Investment & Growth Summit, held March 2 to 3 at Eden Roc Miami Beach, in Miami Beach, Florida, will include innovative programs, one-on-one meetings, and company presentations. For more information please refer to the conference website at

    2/24/26 7:30:00 AM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Smith+Nephew signs distribution agreement with SI-BONE

    Trauma and Extremities partnership aligns disciplined approach to portfolio optimization and focuses on delivering long-term value for surgeons and patients  Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announced it has signed a distribution agreement with SI-BONE, focused on their innovative iFuse TORQ portfolio. This collaboration expands the Smith+Nephew portfolio offerings for percutaneous pelvic fracture fixation procedures and strengthens our position in high-frequency, high-impact trauma procedures."We're incredibly excited to partner with SI-BONE," said Scott Gunn, Vice President Trauma, Extremities and Shoulder. "This collaboration reflects a share

    2/23/26 4:30:00 PM ET
    $SIBN
    $SNN
    Medical/Dental Instruments
    Health Care
    Industrial Specialties

    SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2025 and Issues 2026 Guidance

    Achieves 20% worldwide revenue growth and positive adjusted EBITDA for Fiscal Year 2025Generates free cash flow in the Fourth Quarter 2025 SANTA CLARA, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $56.3 million, representing growth of 15.0%U.S. revenue of $53.5 million, representing growth of 13.9%Gross margin of 79.0%Net loss of $1.6 million, r

    2/23/26 4:09:00 PM ET
    $SIBN
    Medical/Dental Instruments
    Health Care

    $ADTX
    $AKLI
    $BIOL
    $CANF
    SEC Filings

    View All

    SEC Form S-8 filed by SI-BONE Inc.

    S-8 - SI-BONE, Inc. (0001459839) (Filer)

    2/24/26 4:31:47 PM ET
    $SIBN
    Medical/Dental Instruments
    Health Care

    SEC Form S-3ASR filed by SI-BONE Inc.

    S-3ASR - SI-BONE, Inc. (0001459839) (Filer)

    2/24/26 4:26:23 PM ET
    $SIBN
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by SI-BONE Inc.

    10-K - SI-BONE, Inc. (0001459839) (Filer)

    2/24/26 4:19:29 PM ET
    $SIBN
    Medical/Dental Instruments
    Health Care

    $ADTX
    $AKLI
    $BIOL
    $CANF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Recupero Anthony J sold $324,204 worth of shares (21,049 units at $15.40), decreasing direct ownership by 8% to 243,418 units (SEC Form 4)

    4 - SI-BONE, Inc. (0001459839) (Issuer)

    2/18/26 7:52:05 PM ET
    $SIBN
    Medical/Dental Instruments
    Health Care

    SVP, Ops & Adm/Chief Legal Ofr Pisetsky Michael A. was granted 78,294 shares and sold $318,642 worth of shares (20,756 units at $15.35), increasing direct ownership by 25% to 285,974 units (SEC Form 4)

    4 - SI-BONE, Inc. (0001459839) (Issuer)

    2/18/26 7:16:03 PM ET
    $SIBN
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Francis Laura was granted 229,481 shares and sold $1,432,122 worth of shares (93,475 units at $15.32), increasing direct ownership by 33% to 544,369 units (SEC Form 4)

    4 - SI-BONE, Inc. (0001459839) (Issuer)

    2/18/26 7:15:17 PM ET
    $SIBN
    Medical/Dental Instruments
    Health Care

    $ADTX
    $AKLI
    $BIOL
    $CANF
    Financials

    Live finance-specific insights

    View All

    SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2025 and Issues 2026 Guidance

    Achieves 20% worldwide revenue growth and positive adjusted EBITDA for Fiscal Year 2025Generates free cash flow in the Fourth Quarter 2025 SANTA CLARA, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $56.3 million, representing growth of 15.0%U.S. revenue of $53.5 million, representing growth of 13.9%Gross margin of 79.0%Net loss of $1.6 million, r

    2/23/26 4:09:00 PM ET
    $SIBN
    Medical/Dental Instruments
    Health Care

    SI-BONE To Present at TD Cowen 46th Annual Health Care Conference on March 2, 2026

    SANTA CLARA, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA. Management will be hosting a fireside chat on Monday, March 2, 2026, at 7:30 a.m. Pacific Time/ 10:30 a.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/hkU3gw9TuYE3fDbRaRPY9r. Live audio of the webcast will be available on the "Investors" sect

    2/17/26 4:30:00 PM ET
    $SIBN
    Medical/Dental Instruments
    Health Care

    Star Equity Holdings, Inc. Declares Cash Dividend of $0.25 Per Share of 10% Series A Cumulative Perpetual Preferred Stock

    OLD GREENWICH, Conn., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Star Equity Holdings, Inc. (NASDAQ:STRR) ("Star" or the "Company"), formerly Hudson Global, Inc. (NASDAQ:HSON), a diversified holding company, announced today that its Board of Directors declared a cash dividend to holders of the Company's 10% Series A Cumulative Perpetual Preferred Stock of $0.25 per share. The record date for this dividend is March 1, 2026, and the payment date is March 10, 2026. About Star Equity Holdings, Inc. Star Equity Holdings, Inc. is a diversified holding company that seeks to build long-term shareholder value by acquiring, managing, and growing businesses with strong fundamentals and market opportunities.

    2/13/26 8:30:00 AM ET
    $HSON
    $STRR
    Professional Services
    Consumer Discretionary

    $ADTX
    $AKLI
    $BIOL
    $CANF
    Leadership Updates

    Live Leadership Updates

    View All

    Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx

    Proposed acquisition will add new anatomic pathology services, proprietary PCR tests and a national client base Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it has entered into a definitive agreement to acquire selected assets of Bako Diagnostics ("Bako"), a premier pathology laboratory headquartered in Alpharetta, GA and to acquire StrataDx, a premier dermatopathology laboratory located in Lexington, MA. Fulgent will acquire certain assets of Bako Diagnostics and will acquire StrataDx for a total combined purchase price of approximately $55.5 m

    12/22/25 4:10:00 PM ET
    $FLGT
    Medical Specialities
    Health Care

    NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris

    PARIS and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) --  NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that following the annual review of the Euronext Paris indices, the Scientific Council of the Indices has decided to admit Nanobiotix to both the CAC Mid 60 and SBF 120 indices. These changes will become effective after the market closes on Friday, December 19, 2025. The CAC Mid 60 and SBF 120 indices represent two of the most widely followed benchmarks for mid-sized and leading liste

    12/15/25 2:30:00 AM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor

    Contributing Broad Business and Government Affairs Expertise and Network PRINCETON, N.J., Sept. 23, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the appointment of Tomas J. Philipson, PhD as a Strategic Advisor. Dr. Philipson is considered an expert in United States (U.S.) economic policy, particularly health care policy, and frequently appears on major media outlets, including F

    9/23/25 7:30:00 AM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $AKLI
    $BIOL
    $CANF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SI-BONE Inc.

    SC 13G/A - SI-BONE, Inc. (0001459839) (Subject)

    11/14/24 6:27:27 PM ET
    $SIBN
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Can-Fite Biopharma Ltd Sponsored ADR (Israel)

    SC 13G/A - Can-Fite BioPharma Ltd. (0001536196) (Subject)

    11/14/24 4:48:49 PM ET
    $CANF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by SI-BONE Inc.

    SC 13G - SI-BONE, Inc. (0001459839) (Subject)

    11/14/24 4:43:38 PM ET
    $SIBN
    Medical/Dental Instruments
    Health Care